Pimasertib Hydrochloride/Voxtalisib

N/A

Report date: 2022/01/29 17:55:21

Base Information

Drug NamePimasertib Hydrochloride/Voxtalisib

Drug Alias Namevoxtalisib/pimasertib hydrochloridevoxtalisib + pimasertib hydrochloridepimasertib hydrochloride+Voxtalisib

ClassificationSmall molecules

Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsmTOR Complex 2 inhibitorsPhosphatidylinositol 3 kinase alpha inhibitors +[5]

TargetsDual specificity mitogen-activated protein kinase kinase 2Mammalian target of Rapamycin (mTORC1)mTOR Complex 2 +[5]

Therapy Area/IndicationsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Voxtalisib Hydrochloride Pimasertib hydrochloride

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMerck & Co Inc Sanofi

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSanofi Merck & Co Inc

Active IndicationsN/A

Inactive IndicationsOvarian Neoplasms

Other Information

ATC CodeN/A